Clinical Trials
72
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (51 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients
- Conditions
- Essential Thrombocythaemia
- Interventions
- Drug: Ropeginterferon alfa-2b (BESREMi®)
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AOP Orphan Pharmaceuticals AG
- Target Recruit Count
- 117
- Registration Number
- NCT06514807
- Locations
- 🇦🇹
University Hospital Graz, Department of Internal Medicine, Clinical Department of Hematology, Graz, Styria, Austria
🇦🇹Medical University Innsbruck, Department of Internal Medicine V (Hematology and Oncology), Innsbruck, Tyrol, Austria
🇦🇹Ordensklinikum Linz GmbH Elisabethinen Hospital, Department of Internal Medicine I - Hemato-Oncology, Linz, Upper Austria, Austria
A Prospective Non-interventional Observational Study to Observe Long-term Treatment and Outcomes in Pulmonary Arterial Hypertension (PAH) Patients
- Conditions
- Pulmonary Arterial Hypertension
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- AOP Orphan Pharmaceuticals AG
- Target Recruit Count
- 110
- Registration Number
- NCT06445673
- Locations
- 🇦🇹
Ordensklinikum Linz, Linz, Austria
🇦🇹Medical University Vienna, Vienna, Austria
🇨🇿Fakultní Nemocnice Olomouc, Olomouc, Czechia
Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- AOP Orphan Pharmaceuticals AG
- Target Recruit Count
- 20
- Registration Number
- NCT06350032
- Locations
- 🇸🇰
Pediatric Cardiac Center, Bratislava, Slovakia
🇦🇹Medizinische Universität Wien, Vienna, Austria
🇫🇷Necker-Enfants Malades Hospital, Paris, Paris, France
Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Generic treprostinil sodium + Standard of Care (Double Oral)Drug: Standard of Care - Double Oral
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- AOP Orphan Pharmaceuticals AG
- Target Recruit Count
- 110
- Registration Number
- NCT06317805
- Locations
- 🇦🇹
Ordensklinikum Linz, Linz, Austria
🇦🇹Medical University Vienna, Vienna, Austria
🇨🇿Fakultní Nemocnice Olomouc, Olomouc, Czechia
Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients
- Conditions
- Polycythemia Vera
- Interventions
- Drug: Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen
- First Posted Date
- 2015-08-14
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- AOP Orphan Pharmaceuticals AG
- Target Recruit Count
- 30
- Registration Number
- NCT02523638
- Locations
- 🇦🇹
LKH Graz, Graz, Austria
🇦🇹University Hospital Innsbruck, Innsbruck, Austria
🇦🇹Elisabethinen Hospital Linz, Linz, Austria
- Prev
- 1
- 2
- 3
- Next